Sato_2010_Clin.Pharmacol.Ther_88_335

Reference

Title : The effect of donepezil treatment on cardiovascular mortality - Sato_2010_Clin.Pharmacol.Ther_88_335
Author(s) : Sato K , Urbano R , Yu C , Yamasaki F , Sato T , Jordan J , Robertson D , Diedrich A
Ref : Clinical Pharmacology & Therapeutics , 88 :335 , 2010
Abstract :

The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 (P = 0.045, 95% confidence interval 0.46-0.99) and 0.54 (P = 0.042, 95% confidence interval 0.30-0.98), respectively. The apparent survival benefit in donepezil-treated patients should not be overinterpreted. Prospective clinical trials are warranted.

PubMedSearch : Sato_2010_Clin.Pharmacol.Ther_88_335
PubMedID: 20664535

Related information

Citations formats

Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A (2010)
The effect of donepezil treatment on cardiovascular mortality
Clinical Pharmacology & Therapeutics 88 :335

Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A (2010)
Clinical Pharmacology & Therapeutics 88 :335